Traditional methods for addressing chronic wounds focus on correcting dysfunction by controlling extracellular elements. This review highlights technologies that take a different approach -enhancing chronic wound healing by genetic modification to wound beds. Featured cutaneous transduction/transfection methods include viral modalities (ie adenoviruses, adeno-associated viruses, retroviruses and lentiviruses) and conventional non-viral modalities (ie naked DNA injections, microseeding, liposomal reagents, particle bombardment and electroporation). Also explored are emerging technologies, focusing on the exciting capabilities of wound diagnostics such as pyrosequencing as well as site-specific nuclease editing tools such as CRISPR-Cas9 used to both transiently and permanently genetically modify resident wound bed cells.
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| INTRODUCTION
Chronic wounds globally affect an estimated 50 million patients causing a huge social and economic impact on patients and communities.
The cost of general wound care is estimated to be $25 billion annually in the United States alone and rapidly growing, mainly due to ageing populations, increasing rates of obesity and the increased occurrence of diabetes. [1] [2] [3] [4] Currently, the approach to managing chronic wounds is based on trying to control the environmental elements of the wound and surrounding tissues. Common standard of care approaches for wound care include the following: debridement (surgical or agent-based) of non-viable tissues, anti-inflammatories, antibiotics, moisture correction with wound dressings, and re-epithelialization and granulation of the wound bed by promotional adjuvants. [5] [6] [7] Unfortunately, these traditional methods for treatment do not always result in either complete or prompt wound closure. Chronic wounds are by their very nature complex because of the myriad of factors which can make each wound uniquely difficult to heal. [8] [9] [10] [11] [12] In response to this immense chronic wound challenge, researchers have explored alternative approaches to augment these traditional therapies, which can broadly be described as tissue regenerative therapies. Tissue regeneration (beyond chronic wound therapy) is categorically a vast, rapidly evolving field spanning from biomaterials to stem cell research and utilizes an array of various effectors such as RNAi and drugs for molecular alteration. 13, 14 The purpose of this review was to investigate a narrowed view of tissue regeneration research in the context of genetic engineering biotechnologies. Moreover, this review explores these methods in terms of chronic wound healing for the primary reason that genetic modification of chronic wounds has special requirements that necessitate focused attention to achieve successful outcomes.
Genetic engineering of chronic wounds is an especially exciting and relevant topic because of the rapid developments in the field that are well suited to cutaneous targets and additionally allow for potential patient-specific wound therapy -an outcome not previously possible. This patient-specific treatment paradigm is characterized by technology developments in three interrelated areas which are the focus of this review and include the following: wound diagnostic technologies which help characterize patient-specific molecular factors impacting wound healing, precision gene editing molecular tools such as CRISPR-Cas9 used to correct molecular deficiencies, and enhanced gene delivery biotechnologies that more effectively modify cellular targets with fewer unwanted sequela. 
| WOUND DIAGNOSTICS

| GENETIC MODIFICATION CHALLENGES
In order to properly provide context to the current status of gene editing biotechnologies in chronic wound care, it is necessary to first understand its roots as it relates to major milestones achieved using more traditional methods of viral transduction and non-viral transfection (ie direct DNA injections, liposomal agents, particle bombardment, electroporation).
As part of a brief survey of these technologies, this review will provide insights into what researchers have learned from these investigations and how these principles are or can be applied to the specific performance requirements for chronic wound healing. While this discussion is relatively brief, the reader may find additional information in the supplemental material (see Supplemental Material: Viral Transduction and Conventional Non-Viral Transfection) and in references.
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| VIRAL TRANSDUCTION
Re-purposing viral vectors with the desired therapeutic molecular load is a historically classical approach to genetic modification of cutaneous target cells. While this has been carried out with several virus types in other areas of gene medicine, primarily four virus types have been used specifically in wound-healing applications, which include the following: adenovirus, adeno-associated virus and the retroviridae family (retrovirus and lentivirus).
In terms of usage, adenovirus (ADV) has been the most widely used viral vector in chronic wound-healing animal experimentation research (see Table S1 for a listing of animal experimentation research with Viral Again, though, AAV has several limiting features that make usage in wound therapy a challenge and include the following: requires high multiplicity of infection (MOI) to transduce cells 28 and has a relatively low pay load capacity of 4-kb. 31 Other viruses have been employed to improve upon these barriers experienced by AAV but due to other intrinsic limitations have not been widely used. [48] [49] [50] [51] [52] [53] ) have focused on direct, in vivo modification of resident cells (see Figure S4 for more information about non-viral transfection mechanisms). One of the challenges with this type of approach is that chronic wound beds are missing rich cellular targets for gene modification, making it difficult to leverage a widespread benefit. Moreover, many of these direct insertion approaches have had less success than desired in terms of molecular expression or wound-healing times mainly because of the inability to keep the DNA intact in the extracellular environment as well as the poor delivery of the DNA across the target cells' outer membrane.
| CONVENTIONAL NON-VIRAL TRANSFECTION
| KEY INSIGHTS OBTAINED FROM CONVENTIONAL MODIFICATION TECHNIQUES
The viral transduction and conventional non-viral transfection methods surveyed briefly up to this point have not completely provided a satisfactory solution to the problems surrounding genetic modification of chronic wounds. As shown in Table S1 , several animal experimentation studies have explored these conventions with various degrees of success. Unfortunately, none of these techniques have gone on to clinical trial.
Nevertheless, there are key insights that can be gained and transformed into performance requirements, which help to define the path forward for future cutaneous genetic modification. These modification requirements are shown in Figure 2 .
Given these criteria in the context of previously applied conventional genetic biotechnologies, the following details emerging technologies that integrate these critical performance measures in wound applications and expand the strategic modification of wound beds to also include in vitro modalities.
| EMERGING CONCEPTS
| CRISPR-Cas9 genomic target modification
A critical interplay exists between the logistical delivery of genetic pay loads and the native biologic mechanisms in target cells that promote expression of the exogenous DNA. In the case of viral transfection, this interplay is clearly integrated because the virus is involved in the delivery as well as the expression of the desired gene. In the case of conventional non-viral transfection, this interplay is not integrated and historically been a major source for reduced efficiency in expression rates relative to viral methods.
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F I G U R E 1 General differences between viral transduction and non-viral transfection. Note: Green plus signs are features viewed as positive characteristics, while red "x" marks are viewed as negative characteristics
F I G U R E 2 Key insights for genetic modification of chronic wounds obtained from conventional viral transduction and non-viral transfection methods as it relates to prior animal experimentation studies
Fortunately, a relatively new nuclease editing tool, known as CRISPR-Cas9, has been developed which can facilitate meeting many of the stated wound-healing criteria when coupled with an efficient physical delivery modality ( 
| New delivery systems
Unlike conventional delivery systems mentioned previously that primarily focus on direct, in vivo wound modification using a traditional promoter gene plasmid, newer delivery modalities are more efficiently managing the specific performance requirements of cutaneous modification (Table 1 to see how these emerging methods generally satisfy requirements outlined in Figure 2 ). This partly occurs as these new 
| Conjugated nanoparticles
Conjugated nanoparticles can be generally described as nano-sized (~50 to 250 nm diameters) materials that can be functionalized with a range of molecules that permit the particle to carry desirable biologic loads (such as DNA, drugs, growth factors). These constructs are of particular interest because of the broad flexibility to both customize behavioural outcomes of the conjugate via material selection of the nanoparticle and the functionalization of its surface. For instance, supra-paramagnetic conjugated nanoparticles can be complexed with viral components (helps with tissue tropism) or nucleic acids such that in externally applied magnetic fields, the complexes can be directed in vivo towards cellular targets. 75 This ability to direct transfection via the magnetic field has been shown to increase transfection rates up to 40-fold higher than samples not exposed to magnetic fields. 76 Furthermore, because of the magnetic activity of the complex, the conjugates can be monitored via MRI during the transfection process, a coupled process that combines diagnostics with gene therapy (also known as theranostics).
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While there is limited research that has been applied to cutaneous wounds using conjugated nanoparticles, there is precedence of effective gene transfer using functionalized nanoparticles in other clinical applications. 
| Multi-electrode arrays
Multi-electrode arrays (MEA) consist of a grid patterning of blunt electrodes that unlike prior generations of electroporation microneedles does not penetrate the skin in order to locally permit transgene delivery to the skin. 80 The utility of MEA has been explored in terms of proof-ofconcept work in guinea pig skin (structurally similar to human skin), [81] [82] [83] where gene transfer has been shown to affect the epidermis and that skin damage as a result of the electrical exposure was shown to be recoverable. Furthermore, Guo et al. 83 demonstrated using this animal model, the effects of human factor IX protein production following gene electrotransfer using MEA. Notably, it was shown that human factor IX expression was significantly increase in the skin (from 2 to 21 days posttreatment) and had some increases in the circulating blood.
These findings regarding MEA are important in terms of potential wound-healing techniques for several reasons. First, unlike traditional electroporation methods, MEA uses much lower applied voltages to induce transient pore formation, which is likely the reason for improved tissue recovery following MEA verses traditional electroporation. Second, shown in the guinea pig studies, in vivo penetration is sufficient to achieve epidermal regeneration, an aspect not as clearly defined in prior technologies such as particle bombardment methods.
Third, demonstration of increasing protein production in the local circulation environment via MEA application is an important concept in potential angiogenesis and wound healing. Although human factor IX is not as relevant in the chronic wound-healing cascade, this work does mark an important concept that could be applied in wound healing. One technology that is a hybridization of microneedle physical delivery design in concert with localized electroporation in a pseudomulti-electrode array fashion is a technology called nanoinjection.
| Microfabricated needle and nanowire arrays
More specifically, first-generation nanoinjection consisted of a microelectromechanical system (MEMS) that uses electrostatic attraction of DNA onto a silicon micro-sized solid lance that is then inserted into mouse embryos before electrically releasing exogenous DNA into the host.
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This same technology has been modified in a second generation to consist of a microfabricated silicon wafer that has a grid of four million 10-micron-length lances that allow for effective delivery of genetic loads to hundreds of thousands of cells simultaneously. 92, 93 As an emerging method, nanoinjection shows promise in regard to in vitro CRISPR-Cas9 chronic wound applications, given the high efficiency of transfection and high cell survival rates 94 as well as the lack of cytotoxic effects.
| CONCLUSION
Chronic wounds are complicated skin environments that can fail to 
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